Peptide 204-212 of lipocortin 5 inhibits the generation of a prostacyclin-like factor from rat aorta preparations in vitro

Prostaglandins. 1992 Nov;44(5):381-8. doi: 10.1016/0090-6980(92)90134-f.

Abstract

The release of an endogenous prostacyclin-like factor (PLF) from rat thoracic aorta rings was evaluated through inhibition of platelet ADP-induced aggregation and assessed with a micro-method using 96-multiwell plates. Aggregation was assessed in an ELISA reader by measuring changes of optical density at 620 nm in each well. The generation of endogenous PLF by aortic rings was time-dependent and was inhibited by indomethacin (3 microM). ADP-induced aggregation was inhibited by iloprost in a dose-dependent manner. Incubation of rat aorta rings with peptide 204-212 of human lipocortin 5 (1-100 micrograms/ml) resulted in a dose-dependent inhibition of PLF release with a maximal inhibition of 90-95%. The effect of peptide 204-212 was reversible. A control peptide (amino-acids 104-112 of lipocortin 5) was without any significant effect. Peptide 204-212 (100 micrograms/ml) did not modify PLF release from rat aorta preparations challenged with arachidonic acid (10(-6)-10(-4) M).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Annexin A5 / chemistry
  • Annexin A5 / pharmacology*
  • Arachidonic Acid / pharmacology
  • Dose-Response Relationship, Drug
  • Epoprostenol / metabolism*
  • Iloprost / pharmacology
  • In Vitro Techniques
  • Male
  • Molecular Sequence Data
  • Peptide Fragments / pharmacology
  • Platelet Aggregation / drug effects*
  • Rats
  • Rats, Wistar

Substances

  • Annexin A5
  • Peptide Fragments
  • Arachidonic Acid
  • Epoprostenol
  • Iloprost